Pulmonary veno-occlusive disease
in a HIV-infected intravenous drug abuser.
of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.
Etiology from most prevalent to least was as following: congenital heart diseases (27%), chronic thromboembolic pulmonary hypertension (24%), connective tissue diseases-scleroderma (14%), idiopathic PAH (8%), diastolic dysfunction (3%), pulmonary disease (3%), pulmonary veno-occlusive disease
(2%), hepatopulmonary hypertension (1%), and HIV-infection associated PAH (1%).
Pharmacokinetics of busulfan: correlation with veno-occlusive disease
in patients undergoing bone marrow transplantation.
Food and Drug Administration today approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease
(VOD) with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation (HSCT).
Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease
and pulmonary capillary hemangiomatosis.
He published the seminal report of hepatic veno-occlusive disease
after BMT in the SAMJ.
Defibrotide is being developed for the prevention and treatment of Veno-Occlusive Disease
(VOD) in stem cell transplant recipients.
However, high-dose BU is also associated with serious organ toxicity such as central nervous system toxicity or veno-occlusive disease
(VOD) of the liver (5).
Jazz Pharmaceuticals distributes defibrotide in the European Union (EU) under the name Defitelio for the treatment of severe hepatic veno-occlusive disease
(VOD) in patients over one month of age undergoing hematopoietic stem cell transplantation (HSCT) therapy.